Celecoxib 400mg + Placebo
Phase 3Recruiting 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Depressive Disorder, Major
Conditions
Depressive Disorder, Major, Inflammation
Trial Timeline
Sep 28, 2022 → Jul 1, 2026
NCT ID
NCT05415397About Celecoxib 400mg + Placebo
Celecoxib 400mg + Placebo is a phase 3 stage product being developed by Brain Biotech for Depressive Disorder, Major. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05415397. Target conditions include Depressive Disorder, Major, Inflammation.
What happened to similar drugs?
20 of 20 similar drugs in Depressive Disorder, Major were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05415397 | Phase 3 | Recruiting |
Competing Products
20 competing products in Depressive Disorder, Major
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| duloxetine | Eli Lilly | Pre-clinical | 26 |
| Duloxetine Hydrochloride | Eli Lilly | Pre-clinical | 26 |
| LY2216684 | Eli Lilly | Phase 1 | 29 |
| LY2216684 | Eli Lilly | Phase 1 | 29 |
| Duloxetine | Eli Lilly | Phase 3 | 40 |
| LY2216684 + Digoxin | Eli Lilly | Phase 1 | 29 |
| Duloxetine + Paroxetine | Eli Lilly | Phase 3 | 40 |
| Duloxetine + placebo | Eli Lilly | Phase 3 | 40 |
| LY2216684 + Placebo + Escitalopram | Eli Lilly | Phase 2 | 35 |
| FK949E | Astellas Pharma | Phase 1 | 29 |
| quetiapine extended release (XR) + Placebo | Astellas Pharma | Phase 2 | 35 |
| FK949E | Astellas Pharma | Phase 1 | 29 |
| FK949E | Astellas Pharma | Phase 1 | 29 |
| FK949E | Astellas Pharma | Phase 1 | 29 |
| Mirtazapine Tablets | Sun Pharmaceutical | Approved | 43 |
| Duloxetine Hydrochloride | Shionogi | Phase 3 | 32 |
| Duloxetine Hydrochloride + Placebo | Shionogi | Phase 3 | 40 |
| ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1 | Ono Pharmaceutical | Phase 2 | 35 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 39 |
| Pramipexole ER + Escitalopram | Cipla | Phase 2 | 42 |